chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shortness of Breath; Facial Numbness; eyesight problems Can't see past his foot; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Shortness of Breath), HYPOAESTHESIA (Facial Numbness) and VISUAL IMPAIRMENT (eyesight problems Can't see past his foot) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. O46B21A) for COVID-19 vaccination.     no medical history was reported by reporter.  Concomitant products included TESTOSTERONE CIPIONATE (DEPO-TESTOSTERONE), BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (SUBOXONE), LISINOPRIL and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced DYSPNOEA (Shortness of Breath), HYPOAESTHESIA (Facial Numbness) and VISUAL IMPAIRMENT (eyesight problems Can't see past his foot). At the time of the report, DYSPNOEA (Shortness of Breath), HYPOAESTHESIA (Facial Numbness) and VISUAL IMPAIRMENT (eyesight problems Can't see past his foot) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Apr-2021, Blood pressure measurement (140/90-Unknown mmHg): 200/120 mmHg (High) elevated blood pressure.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Pruritis, hives, no airway issues. Given solu-MEDROL, benadryl, pepcid, IVF. Improved.   Please email for further disposition as still in ED.
Pt started with rash on L arm just inferior to vaccination site about 10 days after first vaccine Got a bit better, but then got more red and itchy about 2 wks after 2nd vaccine was administered at the same site on 2/18 hydrocortisone 1% and benadryl 25 mg helping a little, have modified to using triamcinolone 0.1% and claritin 10 mg as well
Intense shivers and feeling cold although the environment was warm around 10p and occurring through the night. Uneasy sleep. Migraine and sore eyes upon waking. Significant vertigo and syncope. Achy head through the day. Some nasal congestion and sore throat. Symptoms began to subside at 9p, except lingering aches and overall feeling unwell.
"Pfizer-Bio-Tech COVID-19 Vaccine EUA"  After receiving the Covid-19 vaccine at 12:15 pm client compliant of having tingling lip and tongue symptoms. She stated that she has anxiety and had the same symptoms with the 1st vaccine and received liquid Benadryl. He brought in a note from the allergist that the benefit outweighs the risk and individual should be given vaccine in a controlled environment. 12:15 patient received 25 mg po of Benadryl elixir by mouth 99% Sat's, 156/90,79,20; 12:20 pm v/s 158/92, 56, 20, 99%, 12:25 PM, v/s, 150/90, 56, 18, 99%. Individual was monitor for 30 minutes and stated her can barely felt the tingling in her lips and tongue. Discharge vitals at 12:43 pm 146/92, 58, 18, 98 %.
Initial unsolicited report received from a consumer on 17 November 2016. This case involves a 57-years-old female patient who was vaccinated with a dose of Fluzone (batch number UH893AB, expiry date, dose, site of administration were not reported) via intramuscularly route on 26 November 2013. Illness at time of vaccination reported as no and pre-existing physician diagnosed allergies, birth defects, medical conditions were reported as none. Concomitant medications were not reported. On 26 November 2013, same day following the vaccination patient felt itchy and on 27 November 2013 (next day), patient experienced itchy rashes. On unspecified date, following the vaccination patient experienced skin discoloration where the rash had been. It was reported that patient did see an allergist for symptoms. Lab data was and corrective treatment was not reported. On unspecified date, patient recovered from events. List of documents held by sender: none.
Patient had previously received the Janssen (J&J) vaccine at Practice on 4/7/2021.  This violates the EUA for both vaccine parameters.
patient admitted for chest pain and code MI.  elevated troponin with normal coronary, 0.5-1 mm ST elevation in inferior leads and V5 when troponin was positive at 0.5.  MD stated patient is diagnosed with myocarditis.
sore arm; headache; chills; Nausea; Diarrhea; body aches; feels like the flu; fever; difficulty breathing; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (sore arm), HEADACHE (headache), CHILLS (chills), NAUSEA (Nausea) and DIARRHOEA (Diarrhea) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046A21A and 047B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included INSULIN.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Apr-2021, the patient experienced PAIN IN EXTREMITY (sore arm), HEADACHE (headache), CHILLS (chills), NAUSEA (Nausea), DIARRHOEA (Diarrhea), PAIN (body aches), INFLUENZA LIKE ILLNESS (feels like the flu), PYREXIA (fever) and DYSPNOEA (difficulty breathing). At the time of the report, PAIN IN EXTREMITY (sore arm), HEADACHE (headache), CHILLS (chills), NAUSEA (Nausea), DIARRHOEA (Diarrhea), PAIN (body aches), INFLUENZA LIKE ILLNESS (feels like the flu), PYREXIA (fever) and DYSPNOEA (difficulty breathing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was reported.   Reporter did not allow further contact
Patient developed rash itching over TDAP injection location 1 wk ago. Failed OTC TYLENOL + BENADRYL. Rash spreading no pain feels well. Developed localized cellulitis. Placed on KEFLEX, MOTRIN, BENADRYL with follow up in 2-3 days at our office.
1 day p/inject devel redness & swelling of rt shoulder area; Seen in ER & treated as possible cellulitis 21SEP91; Seen by MD 23SEP dec swelling;
Pt recv vax on 1/14/98; approx 8 hr post vax pt exp chills & fever x 3 day
Swelling, redness, heat, bruising after 3 days. Pt was Pt used cold packs and warm packs
pt c/o redness, swelling at L Deltoid spreading from injection site, 4 days post receiving immunization. Did not report symptoms until  8 days post immunization.  NP examined student and recommended OTC Zyrtec.
Three days after vaccination, the patient was working outside when he suddenly died.  Specific events are not known as he was alone at his work site. No bodily injuries were found. He was simply passed out and unresponsive when found. He had been deceased for hours upon his discovery.
After her second dose, she experienced 3 -4 bloody noses for the first few days post jab; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program.  A 94 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administration date 09Mar2021 10:30 (Batch/Lot number: unknown) at the age of 93 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose:1, Time (24hrs): 10:00 am, Site and Route of injection:, Anatomical site of injection: Shoulder, Route of administration: Intramuscular), administration date: 15Feb2021, when the patient was 93 years old, for COVID-19 Immunization. The following information was reported: EPISTAXIS (non-serious) with onset 10Mar2021 03:00, outcome "recovered" (Jul2021), described as "After her second dose, she experienced 3 -4 bloody noses for the first few days post jab".  Additional information: It was unknown if patient had Prior vaccinations (within 4 weeks).No relevant test were done.Post 2nd Vax onset of bloody nose events daily for about 10 days, then only 4 or 5 /week-eventually tapering off to one event every 2-3 weeks-subsided completely by mid Jul2021.For Dose 2 Anatomical site of injection: Shoulder.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The patient fainted during administration of HBV. The patient appeared to be looking down, then snored. When spoken to, she awakened quickly. Her pulse was 60 and regular. The patient remained sitting upright but was pale. The patient stated she felt weird, but was alright.
This spontaneous report as received from a Medical Assistant refers to a 16 year old patient. On 10-MAY-2013 the patient was vaccinated with an expired dose of M-M-R II (lot # 670618/0567AA, exp date 15-APR-2013) (dose and route was not reported), as the second dose of M-M-R II (date of first dose of M-M-R II was unspecified). No adverse event reported. Additional information has been requested.
This is a spontaneous report received from a noncontactable consumer or other non-HCP, for a Pfizer sponsored program (159558). A patient (no qualifiers provided) received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. The patient had illness (become ill after the 1st dose), with outcome of unknown. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old male patient received BNT162b2 (BNT162B2), on 10Apr2021 as dose 1, single (Lot number: ER8734), on 01May2021 as dose 2, single (Lot number: ER8736) and on 15Jan2022 as dose 3 (booster), single (Lot number: FK9729) at the age of 55 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 12Nov2022, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: Body temperature: (Nov2022) Result unknown; Oxygen saturation: (Nov2022) Result unknown; SARS-CoV-2 test: (13Nov2022) Positive; Vital signs measurement: (unspecified date) Unknown.  Clinical course: Reporter States that he took his mom to the hospital on Saturday, 12Nov2022, and found out that she was positive for Covid. Saturday night he had a sore throat and a cough. He did a self test on Sunday, 13Nov2022 and it was positive for COVID-19. He called his transplant team and he went in for monoclonal antibodies yesterday. His symptoms are mild. He has a runny nose and today his body hurts. States that he monitors his vital signs 4 times a day anyway and sends his temperature and oxygen levels to the hospital via an app on his phone. His mom is normally his caretaker, so he is doing a lot more activity than he would normally due, so he is having hip issues which is probably from using different muscles to hold himself up with a walker. He thinks his body aches are because he is being more active.
metalic taste; throat tightened up; tachycardia 130-140 x 20 min; dizzyness; fatigue; headache; sore arm; This is a spontaneous report from a contactable consumer(patient). A 57-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID 19 Vaccine, Solution for injection, Lot number: EL1283, Expiration date: Not reported), intramuscular administered in arm right on 07Jan2021 12:00 (at a age of 57-year-old) as dose 2 single and recevied BNT162B2 (PFIZER-BIONTECH COVID 19 VaccineLot number: EH9899, Expiration date: Not reported) intramuscular administered in arm right on 07Dec2020 19:00 as dose 1 singel, for COVID-19 immunisation. Patient previously took the medication included were Loratab, Losartan, Amlodipine. Once received loratab patient become itchy, feels like bugs crawling all over. No significant relevant family history, No there predisposing factors, no was a culture performed. Concomitant medication included paracetamol (TYLENOL, Strength: 160 mg) at 160 mg taken from 07Jan2021 11:00; diphenhydramine hydrochloride (BENADRYL, Strength: 50mg) at 50mg from 07Jan2021 11:00. It was reported that the on 07Jan2021 at 12.00 patient experienced metallic taste, throat tightened up, tachycardia (130-140 within 20 min), dizziness, fatigue. Epipen was available at the time of 2nd injection did not need it. This all happened with in 1st 1 min of receiving the vaccine. No nausea or loose stools did have headache and sore arm lasted 2 days. No treatment needed. The events were considered as non serious. The outcome of the events were recovered, headache and sore arm were recovered on 09Jan2021.
Information has been received from a consumer concerning a female who was vaccinated with GARDASIL (Lot # not provided).  After receiving GARDASIL, the patient got sick.  The outcome of adverse event was not reported.  It was not reported whether the patient sought medical attention.  This was one of several reports from the same source.  Additional information has been requested.
The client complained of "Feeling detached from her surrounding, nausea, dizzy, fatique, feeling heart rate and breathing had increased. Client was oriented, skin color pink, Vital signs:  12:59- b/p 140/100, p 92,  regular rr 22, 1:00 pm b/p 140/95 p 80 rr 24. Client was moved to another room so she could put her head down. 1:15 b/p140/85 p 85 rr 22 . Client expressed she was feeling better. She expressed concerns about her daughter becoming sick once again with COVID and that she was going to be tested. She also expressed that she was going to a co-workers funeral the next day. Pt  refused further medical care however was encouraged to go home early. She agreed and was escorted to her Supervisor for discharge home.
Initial unsolicited report received from a physician via other company (Pfizer) on 15 Sep 2016. Manufacturer Report Number: 2016423144. This case involves a patient (gender and age was not reported) who was vaccinated with a dose of TETANUS TOXOIDS (manufacturer: unknown, batch number, expiry date, dose, dose in series, route and site of administration were not reported) on an unknown date. The patient's medical history includes hyperlipidaemia, diabetes mellitus 2, hypertension (it was unknown whether they are ongoing) and Concomitant medications were not reported. It was reported that the patient was allergic to tetanus toxoids. The patient's laboratory data and corrective treatment was not reported. The outcome of event was not reported. List of documents held by sender: none.
Sudden onset of ringing in the left ear. Has continued from onset to today, 07/09/2021
Allergy; This is a spontaneous report received from a contactable consumer (parent). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 26Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. After the vaccine, like 3 days after she was doing gardening on 29Mar2021, she started having an allergy for some reasons she never had before. Outcome of event was unknown.  No follow-up attempts are possible, information about batch number cannot be obtained.
I am experiencing diarrhea for the last 12 hours and have been having stomach issues since 2 days after receiving the vaccine but don't know if its related.
Pt indicated no prior covid vaccination. After moderna vaccination, he remembered he got Pfizer previously .
Patient made online appointment as first dose then, after we administered the shot he gave us the card and we found out it was 8 days early.  We called Moderna and they told us there is no need to repeat the dose.
Patient received FLUZONE HD. There were no problems with administration. She called pharmacy several days later to inform us that later in the day that she received the vaccination she had sneezing, itching and body aches and felt that way for the next day before beginning to feel better. She wanted us to report this information.
Patient reported to clinic on 5/14/07 the onset on 5/8-or5/9 of a rash on arms bilaterally without pruitus, fever or respiratory distress. Patient coincidentally had a primary care appointment and reported the rash to her PCP, No treatment was instituted. Rash resolved in 1 week without sequelae.
Infant screamed uncontrollably for over 1 hour-L thigh + red, - swelling (PENTACEL site) around 3 1/2" induration-given BENADRYL 6.25 mg PO x 1 and acetaminophen 0.8 cc PO x 1 at 4:27. By 4:55 redness gone and baby calmed. 12/3/09 AM per mom, decreased swelling, doing well.
Malaise, fever, chills, severe chest pain (pleurodynia), tremors, shortness of breath, anxiety.
Within 10-15 minutes of receiving the injection, the patient developed significant swelling and redness at the site (described as baseball size), hives, tightening and irritation of throat though airway remained patent, dizziness.
Red and itchy rash at the site of the vaccine, occupying half of the left upper arm; Red and itchy rash at the site of the vaccine, occupying half of the left upper arm; Pain at the site of administration; This spontaneous case was received on 23-Sep-2020, from other non-health professional via agency (reference number: SEQW20-02193) and concerned a 76-year-old, female patient.     The patient's medical history included eczema, urticaria and allergy to dust and grass. The patient's concomitant medications were not reported.   On 19-Sep-2020, the patient was vaccinated with Fluad (TIV) (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: 0.5 ml, route of administration: intramuscular, anatomical location: left deltoid) for influenza prophylaxis. The batch number was not reported.  On the same date, after receiving Fluad (TIV), the patient experienced pain at the site of administration.   On the next day 20-Sep-2020, the patient developed a red and itchy rash at the site of the vaccine, occupying half of the left upper arm. Patient said that her doctor told her that some might be due to latex and wanted to know if there were latex in the vaccine.  On 23-Sep-2020, the patient recovered from all events.    The reporter did not provide causality assessment.  The reporter assessed these events as non-serious.  Company comment: The patient developed erythema, vaccination site pain and rash pruritic within one day after vaccination with the suspect product, Fluad (TIV). Chronology is plausible. No information about concomitant medications was provided. No alternative aetiology was provided. Considering all information above, causal relationship for all events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).; Sender's Comments: The patient developed erythema, vaccination site pain and rash pruritic within one day after vaccination with the suspect product, Fluad (TIV). Chronology is plausible. No information about concomitant medications was provided. No alternative aetiology was provided. Considering all information above, causal relationship for all events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).
Aches, fever, chills began 13 hrs p/vax; resolved w/in 24 hrs;
booster; covid arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (dose 1, Primary Immunization series complete but unknown manufacturer), for Covid-19 Immunization; Covid-19 vaccine (dose 2, Primary Immunization series complete but unknown manufacturer), for COVID-19 Immunization. The following information was reported: IMMUNISATION (non-serious), outcome "unknown", described as "booster"; LIMB DISCOMFORT (non-serious), outcome "unknown", described as "covid arm".  Additional Information: The patient  been exposed more then once, had the vaccine and was exposed in small space for 4 - 10 hour shifts without contracting covid. Once the patient got the booster, Ithe patient got covid arm. The patient would be willing to be exposed and tested to see if they was anything in  blood that could help.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient had several visits to the ED within 6 weeks of receiving COVID vaccination. DOS: 2/24, 3/6, 3/8. Then on 3/10 he presented to the ED and was subsequently hospitalized for 3 days. He presented to the ED on 3/28 and was subsequently hospitalized for 5 days. He also presented to the ED and was subsequently hospitalized on 4/14 for 6 days.
axillary lymphadenopathy;erythema, baggy edema of entire arm;erythema, baggy edema from shoulder to elbow;
shortly after administration, pt began feeling hot, turned red on her arms, chest and back and felt itchy. we placed a cold pack on the back of her neck but itching persisted so we gave her one 25mg capsule of diphenhydramine (Benadryl) and continued to monitor, pt did state that she gets itchy with flu shots (last took 4 years ago) but never a severe reaction. we monitored her for a total of 45 minutes and she felt better after taking the benadryl. we cautioned her that it could cause drowsiness but she had no one to pick her up. she did state she was very familiar with benadryl as she takes it regularly. called patient about 2 hours later to check up on her and she was fine. feeling alot better.
left arm breaking out in hives; left arm broke out in hives: Was in his left arm all the way into his wrist and has gotten worse; This is a spontaneous report from a contactable consumer (patient). A 53-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), dose 2 via an unspecified route of administration, administered in Arm Right on 18May2021 at 09:05 (at the age of 53 years old)(Batch/Lot Number: EW0185) as 2ND DOSE, SINGLE for covid-19 immunization. Medical history included Heart problems, Stent Placement (Has had 4 stents), blood pressure. Concomitant medication include blood pressure pills which he takes every day (Product Name not provided). No relevant family history was reported. Facility in which the vaccine was administered was a pharmacy. Historical Vaccine includes BNT162B2 dose 1 Lot #: EW0167 on 25Apr2021 in Left Arm and experienced Allergic reaction. No other vaccines were given within 4 weeks. In the morning on 19Mar2021, The patient experienced left arm broke out in hives, left arm broke out in hives: Was in his left arm all the way into his wrist and has gotten worse.  Patient stated he  was worried about breaking out in hives. He has heart problems. Treatment was given for the events. Patient took some Benadryl and stated if this does not clear he is going to the Emergency Room. The clinical outcome of the events was not recovered.    Follow-up attempts completed. No further information expected.
About 12 hours after my shot I began experiencing chills, severe body pain and aches, headache, nausea and fatigue. My fever rose to 101.5 degrees. I was I?ll with these symptoms for three days and continued feeling fatigued for several more days after.  Over the course of the following month I had heavy break thru spotting on and off for almost four weeks despite having had my period regularly the week before my shot  (my period is usually completely predictable because I am on birth control).